The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Maxim Pharmaceuticals, Inc.

Maxim Pharmaceuticals, Inc.
Nasdaq: MAXM
Change
symbol:
     
 PROFILE
Development-stage Maxim Pharmaceuticals is maximizing its product line. The company's Ceplene (formerly Maxamine) is in trials for the treatment of skin cancer and leukemia. With partner Hoffman-La Roche, the firm is developing a potential treatment for renal cancer and hepatitis C using Ceplene and La Roche's interferon-alpha agent in combination. Maxim believes Ceplene protects immune system cells and stimulates them to destroy cancerous cells. It is designed to be administered on an outpatient basis. Maxim Pharmaceuticals is also developing MaxDerm, a topical treatment for cold sores, canker sores, shingles, and burns, as well as oral mucositis, a side effect of chemotherapy.

 COMPETITION
AVANIR Pharmaceuticals (AVN)
Immunex Corporation (IMNX)

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: September
2000 Sales (mil.): 1.40
1-Yr. Sales Growth: 27.3%
Employees: 144
Revenue per employee: $9,722.22

 KEY PEOPLE
• Larry G. Stambaugh
    CEO
• Dale A. Sander
    CFO

 CONTACT INFO
8899 University Center Ln., Ste. 400
San Diego, CA 92122
US
Phone: 858-453-4040
Fax: 858-453-5005
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001